Literature DB >> 42905

Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein.

J E Sealey, S A Atlas, J H Laragh, M Silverberg, A P Kaplan.   

Abstract

Plasma prorenin is an inactive form of renin (EC 3.4.99.19) that can be converted to active renin in acid-treated plasma by an endogenous serine protease that is active at alkaline pH (alkaline phase activation). To identify this enzyme we first tested the ability of Hageman factor fragments, plasma kallikrein (EC 3.4.21.8), and plasmin (EC 3.4.21.7) to activate prorenin in acid-treated plasma. All three enzymes initiated prorenin activation; 50% activation was achieved with Hageman factor fragments at 1 microgram/ml, plasma kallikrein at 2-4 microgram/ml, or plasmin at 5-10 microgram/ml. We then showed that the alkaline phase of acid activation occurred normally in plasminogen-free plasma but was almost completely absent in plasmas deficient in either Hageman factor or prekallikrein; alkaline phase activation was restored to these latter plasmas when equal parts were mixed together. Therefore, both Hageman factor and prekallikrein were required for alkaline phase activation to occur. We then found that, although plasma kallikrein could activate prorenin in plasma deficient in either Hageman factor or prekallikrein, Hageman factor fragments were unable to activate prorenin in prekallikrein-deficient plasma. These studies demonstrate that alkaline phase prorenin activation is initiated by Hageman factor-dependent conversion of prekallikrein to kallikrein which, in turn, leads to activation of prorenin. In this fashion, we have revealed a possible link between the coagulation-kinin pathway and the renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 42905      PMCID: PMC411763          DOI: 10.1073/pnas.76.11.5914

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation.

Authors:  A S Weiss; J I Gallin; A P Kaplan
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

2.  A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma.

Authors:  O D RATNOFF; J E COLOPY
Journal:  J Clin Invest       Date:  1955-04       Impact factor: 14.808

3.  Crystalline acid-labile trypsin inhibitor from bovine blood plasma.

Authors:  F C WU; M LASKOWSKI
Journal:  J Biol Chem       Date:  1960-06       Impact factor: 5.157

4.  [Chemical and pharmacologic differentiation of kallikreins of various origins].

Authors:  E WERLE; L MAIER
Journal:  Biochem Z       Date:  1952

5.  Occurrence of big renin in human plasma, amniotic fluid and kidney extracts.

Authors:  R P Day; J A Luetscher; C M Gonzales
Journal:  J Clin Endocrinol Metab       Date:  1975-06       Impact factor: 5.958

6.  Plasma prorenin: cryoactivation and relationship to renin substrate in normal subjects.

Authors:  J E Sealey; C Moon; J H Laragh; M Alderman
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

7.  Flaujeac trait. Deficiency of human plasma kininogen.

Authors:  K D Wuepper; D R Miller; M J Lacombe
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

8.  Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.

Authors:  R W Colman; A Bagdasarian; R C Talamo; C F Scott; M Seavey; J A Guimaraes; J V Pierce; A P Kaplan
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

9.  Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis.

Authors:  V H Donaldson; H I Glueck; M A Miller; H Z Movat; F Habal
Journal:  J Lab Clin Med       Date:  1976-02

10.  Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma.

Authors:  R J Mandle; R W Colman; A P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

View more
  8 in total

Review 1.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

2.  Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency.

Authors:  B N Bouma; D M Kerbiriou; J Baker; J H Griffin
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

Review 3.  Surface-mediated defense reactions. The plasma contact activation system.

Authors:  R W Colman
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

4.  Active and inactive renin release from rabbit kidney cortex slices: effect of sodium concentration and of furosemide.

Authors:  K A Munday; A R Noble; H K Richards
Journal:  J Physiol       Date:  1982-07       Impact factor: 5.182

5.  Human plasma kallikrein. A rapid purification method with high yield.

Authors:  H Nagase; A J Barrett
Journal:  Biochem J       Date:  1981-01-01       Impact factor: 3.857

6.  Characterization of inactive renin ("prorenin") from renin-secreting tumors of nonrenal origin. Similarity to inactive renin from kidney and normal plasma.

Authors:  S A Atlas; T E Hesson; J E Sealey; B Dharmgrongartama; J H Laragh; M C Ruddy; M Aurell
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

7.  Inactive renin.

Authors:  A R Noble
Journal:  J R Soc Med       Date:  1983-09       Impact factor: 18.000

8.  Polymorphisms at the F12 and KLKB1 loci have significant trait association with activation of the renin-angiotensin system.

Authors:  Nilima Biswas; Adam X Maihofer; Saiful Anam Mir; Fangwen Rao; Kuixing Zhang; Srikrishna Khandrika; Manjula Mahata; Ryan S Friese; C Makena Hightower; Sushil K Mahata; Dewleen G Baker; Caroline M Nievergelt; Sucheta M Vaingankar; Daniel T O'Connor
Journal:  BMC Med Genet       Date:  2016-03-11       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.